-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Russell Investments Group Ltd. Sells 18,425 Shares of FibroGen, Inc. (NASDAQ:FGEN)
Russell Investments Group Ltd. Sells 18,425 Shares of FibroGen, Inc. (NASDAQ:FGEN)
Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,964 shares of the biopharmaceutical company's stock after selling 18,425 shares during the quarter. Russell Investments Group Ltd. owned 0.14% of FibroGen worth $1,537,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in FGEN. Allspring Global Investments Holdings LLC bought a new stake in shares of FibroGen in the 4th quarter worth about $530,000. DekaBank Deutsche Girozentrale increased its stake in FibroGen by 3.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,950 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in FibroGen in the 4th quarter worth about $141,000. Advisor Group Holdings Inc. increased its stake in FibroGen by 90.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 4,236 shares during the period. Finally, Toronto Dominion Bank purchased a new position in FibroGen in the 4th quarter worth about $1,835,000. Institutional investors own 77.35% of the company's stock.
Get FibroGen alerts:FibroGen Stock Performance
NASDAQ FGEN opened at $14.33 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $12.00. FibroGen, Inc. has a one year low of $7.81 and a one year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the previous year, the firm earned ($1.45) EPS. The company's quarterly revenue was up 22.3% compared to the same quarter last year. Equities analysts expect that FibroGen, Inc. will post -3 earnings per share for the current fiscal year.Analyst Ratings Changes
Several research firms recently commented on FGEN. Cowen raised their price target on shares of FibroGen to $14.00 in a research note on Monday. The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. Finally, StockNews.com downgraded shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Articles
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
Russell Investments Group Ltd. lessened its position in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 12.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 127,964 shares of the biopharmaceutical company's stock after selling 18,425 shares during the quarter. Russell Investments Group Ltd. owned 0.14% of FibroGen worth $1,537,000 at the end of the most recent reporting period.
罗素投资集团有限公司(Russell Investments Group Ltd.)最近向美国证券交易委员会(Securities And Exchange Commission)提交的13F文件显示，该公司在第一季度减持了12.6%的FibroGen，Inc.(FGEN-GET评级)。该基金在本季度出售了18,425股后，持有这家生物制药公司的127,964股股票。截至最近一个报告期末，罗素投资集团有限公司拥有FibroGen公司0.14%的股份，价值1,537,000美元。
Several other institutional investors have also recently made changes to their positions in FGEN. Allspring Global Investments Holdings LLC bought a new stake in shares of FibroGen in the 4th quarter worth about $530,000. DekaBank Deutsche Girozentrale increased its stake in FibroGen by 3.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 27,950 shares of the biopharmaceutical company's stock worth $397,000 after buying an additional 1,000 shares during the period. Virginia Retirement Systems ET AL purchased a new position in FibroGen in the 4th quarter worth about $141,000. Advisor Group Holdings Inc. increased its stake in FibroGen by 90.6% in the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 4,236 shares during the period. Finally, Toronto Dominion Bank purchased a new position in FibroGen in the 4th quarter worth about $1,835,000. Institutional investors own 77.35% of the company's stock.
其他几家机构投资者最近也改变了他们在fgen的头寸。AllSpring Global Investments Holdings LLC在第四季度购买了FibroGen的新股，价值约53万美元。德意志银行第四季增持FibroGen股份3.7%DekaBank Deutsche Girozentale在此期间又购买了1,000股，现在拥有27,950股这家生物制药公司的股票，价值39.7万美元。弗吉尼亚退休系统等公司在第四季度购买了FibroGen的一个新头寸，价值约141,000美元。Advisor Group Holdings Inc.在第四季度增持了90.6%的FibroGen股份。Advisor Group Holdings Inc.现在持有这家生物制药公司8,909股股票，价值13万美元，在此期间又购买了4,236股。最后，多伦多道明银行在第四季度购买了FibroGen的一个新头寸，价值约1，83.5万美元。机构投资者持有该公司77.35%的股份。
FibroGen Stock Performance
FibroGen股票表现
NASDAQ FGEN opened at $14.33 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.05 and a beta of 0.87. The company's 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $12.00. FibroGen, Inc. has a one year low of $7.81 and a one year high of $16.91.
周四，纳斯达克fgen的开盘价为14.33美元。该公司市值13.4亿美元，市盈率为-6.05，贝塔系数为0.87。该公司的50日简单移动均线切入位为11.99美元，200日简单移动均线切入位为12.00美元。FibroGen，Inc.的一年低点为7.81美元，一年高位为16.91美元。
Analyst Ratings Changes
分析师评级发生变化
Several research firms recently commented on FGEN. Cowen raised their price target on shares of FibroGen to $14.00 in a research note on Monday. The Goldman Sachs Group reduced their price target on shares of FibroGen from $9.00 to $8.00 and set a "sell" rating on the stock in a research note on Tuesday, May 24th. Finally, StockNews.com downgraded shares of FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
几家研究公司最近对fgen发表了评论。考恩在周一的一份研究报告中将FibroGen的股价目标上调至14.00美元。5月24日，高盛夫妇将FibroGen的股票目标价从9.00美元下调至8.00美元，并在周二的一份研究报告中对该股设定了“卖出”评级。最后，在8月10日星期三的一份研究报告中，StockNews.com将FibroGen的股票评级从“买入”下调至“持有”。
About FibroGen
关于FibroGen
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物制药公司，发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat，该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发，并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Lowe's Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target's Results Cap Upside Potential For Retail Stocks
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 哪些半导体类股准备好迎接价格大幅波动？
- 尽管面临更广泛的经济挑战，矿商的收益仍在上涨
- Lowe‘s在第二季度零售报告中脱颖而出
- 安捷伦科技对Illumina证明了自己的价值
- 塔吉特的业绩上限零售类股的上行潜力
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧